Pulmonary Nocardiosis in a Heart Transplant Patient: Case Report and Review of the Literature

Haddad, François; Hunt, Sharon A.; Perlroth, Mark G.; Valantine, Hannah; Doyle, Ramona L.; Montoya, José G.

doi:10.1016/j.healun.2006.11.002

Cited by 9 publications

(9 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The patient recovered and remained relapse-free after 15 months. This case presentation is consistent with previous reports noting the heightened risk of serious nocardial infections in transplant patients receiving immunosuppressive therapy (14,21,26).…”

supporting

confidence: 92%

Nocardia cyriacigeorgica , an Emerging Pathogen in the United States

Salais¹,

2008

View full text Add to dashboard Cite

Nocardia cyriacigeorgica is recognized as an emerging pathogen in many parts of the world. We present the first case description of invasive N. cyriacigeorgica pulmonary infection in the United States identified to the species level by 16S rRNA and hsp65 sequence analysis. A subsequent retrospective molecular screening of recent Nocardia clinical isolates at our New York City medical center yielded an additional six N. cyriacigeorgica isolates. Because routine laboratory algorithms for the phenotypic identification of Nocardia species are limited in practice, the true prevalence of N. cyriacigeorgica infections may be greater than currently appreciated. Indeed, we present evidence confirming that N. cyriacigeorgica is coincident with the unofficial species designation Nocardia asteroides complex antimicrobial susceptibility pattern type VI and distinct from the N. asteroides sensu stricto strain ATCC 19247 T . As nocardial species identity can predict antimicrobial susceptibility and guide clinical management, we offer simplified phenotypic and molecular protocols to assist the identification of N. cyriacigeorgica.

show abstract

supporting

confidence: 92%

Nocardia cyriacigeorgica , an Emerging Pathogen in the United States

Salais¹,

2008

View full text Add to dashboard Cite

show abstract

“…32 TMP-SMX has also been effective in reducing the incidence of Nocardia, toxoplasmosis, Listeria, and bacterial infections. 33,34 The incidence of toxoplasmosis has de- The last cohort was followed up for an average of 4.5 years. b A significant trend was present (p Ͻ 0.01).…”

Section: Discussionmentioning

confidence: 99%

Changing trends in infectious disease in heart transplantation

Haddad

Deuse

Pham

et al. 2010

The Journal of Heart and Lung Transplantation

Self Cite

View full text Add to dashboard Cite

“…Es sind 80% der infizierten Patienten männlich mit einem Durchschnittsalter von etwa 40 Jahren [11,14]. Die Infektion erfolgt zumeist aerogen oder in selteneren Fällen durch verunreinigte Nahrung oder direkte Infektion im Rahmen eines Traumas [4,15]. Eine Mensch-zu-Mensch-Infektion ist bislang sehr selten dokumentiert [8].…”

Section: Epidemiologie Und äTiologieunclassified

“…Die Infektion kann sich als lokalisierte Krankheit an Haut, Lunge oder Zentralnervensystem (ZNS) zeigen, aber auch von jedem primären Fokus aus systemisch streuen. Die Lungen stellen in 65% der Fälle den primären Manifestationsort dar [4]. Produktiver Husten, Fieber, Dyspnoe, Hämoptysis und pleuritischer Schmerz sind häufige Symptome.…”

Section: Klinische Manifestationunclassified

“…Die heutigen Therapieempfehlungen beruhen auf klinischen Erfahrungen und tierexperimentellen Untersuchungen. Die Kombination aus Trimethoprim und Sulfamethoxazol stellt heute noch die Therapie der Wahl bei der Behandlung der kutanen Nocardiosen dar [4]. Allerdings wurden in den letzten Jahren auch Resistenzentwicklungen unter dieser Therapie beschrieben [11,12].…”

Section: Therapieunclassified

See 1 more Smart Citation

Disseminierte Nocardiose

Heyn¹,

Ozimek

Grabein

et al. 2010

Anaesthesist

View full text Add to dashboard Cite

Nocardiosis is a rarely found bacterial infection in Europe which can particularly affect immunocompromized patients. Localized infections of the dermis and lungs, as well as disseminated infections can be observed. Suspicion of nocardiosis should be reported to the microbiological laboratory so that goal-directed molecular genetic techniques and extended cultivation can be implemented for identification of the causative agent. A multitude of antibiotics can be used for successful therapy but the duration of therapy must be extended over 6-12 months. The mortality of disseminated infections ranges between 15-85% depending on the underlying immune status of the patient. The polymorphic appearance of nocardiosis is described based on the case of an intensive care patient.

show abstract

Pulmonary Nocardiosis in a Heart Transplant Patient: Case Report and Review of the Literature

Cited by 9 publications

References 13 publications

Nocardia cyriacigeorgica , an Emerging Pathogen in the United States

Nocardia cyriacigeorgica , an Emerging Pathogen in the United States

Changing trends in infectious disease in heart transplantation

Disseminierte Nocardiose

Contact Info

Product

Resources

About